Biogen vs Regeneron Pharmaceuticals
Biogen (BIIB) and Regeneron Pharmaceuticals (REGN) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $33.9B
- Last close
- $229.41
- 12 months
- +56.5%
- Market value
- $78.5B
- Last close
- $762.81
- 12 months
- +35.1%
At a glance
- By market value, Regeneron Pharmaceuticals ($78.5B) is about 2.3 times Biogen ($33.9B).
- Over the last 12 months Biogen's share price moved +56.5% and Regeneron Pharmaceuticals's +35.1%; against the S&P 500 that is +37.4 points and +15.9 points.
- In their last fiscal years Biogen kept 13.1% of revenue as net income and Regeneron Pharmaceuticals 31.4%.
- In the last 90 days insiders reported 0 open-market purchases at Biogen and 0 at Regeneron Pharmaceuticals; members of Congress disclosed 3 trades in Biogen and 1 in Regeneron Pharmaceuticals.
- Next results: Biogen Oct 28, 2026, Regeneron Pharmaceuticals Oct 30, 2026.
Share price over the last 12 months
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Biogen BIIBNASDAQ · Biotechnology | Regeneron Pharmaceuticals REGNNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $33.9B | $78.5B |
| Revenue, last fiscal year | $9.89B | $14.3B |
| Net income, last fiscal year | $1.29B | $4.5B |
| Net marginNet income as a share of revenue | 13.1% | 31.4% |
| Free cash flow | $2.05B | $4.08B |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Biogen against
Common questions
How do Biogen and Regeneron Pharmaceuticals compare in size?
Regeneron Pharmaceuticals has the larger market value: Biogen $33.9B and Regeneron Pharmaceuticals $78.5B, at the last close.
Whose share price rose more over the last 12 months, BIIB or REGN?
Over the last 12 months Biogen moved +56.5% and Regeneron Pharmaceuticals +35.1%. Past price moves say nothing about the future.
Which has had more insider buying, Biogen or Regeneron Pharmaceuticals?
Since 2006, Regeneron Pharmaceuticals insiders reported 551 open-market purchases against 34 for Biogen. These are counts of what was filed, not a view on either stock.
Do members of Congress trade BIIB or REGN?
In the last 12 months, members of Congress disclosed 9 trades in Biogen (BIIB) and 4 in Regeneron Pharmaceuticals (REGN).
When did insiders last buy BIIB and REGN?
Biogen: Feb 18, 2026. Regeneron Pharmaceuticals: Aug 25, 2017.
See the record behind any of these
Each company page opens free with one real filing and the counts of the last 12 months. OQRO Pro adds the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Biogen pageRegeneron Pharmaceuticals pageRare insider trades this weekAll comparisons
https://oqro.io/compare/biib-vs-regn
